# Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06616961` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06616961](<https://clinicaltrials.gov/study/NCT06616961>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06616961

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 480 participants.

## Technical summary

Registry record NCT06616961. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-01 (anticipated); primary completion 2025-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 480 participants (planned count; ClinicalTrials.gov record NCT06616961, source copy `cardio:ctgov-nct06616961-2024-09-27`, retrieved 2026-11-18)
- Planned start: 2024-11-01 (anticipated) (ClinicalTrials.gov record NCT06616961, source copy `cardio:ctgov-nct06616961-2024-09-27`, retrieved 2026-11-18)
- Primary completion: 2025-02 (anticipated) (ClinicalTrials.gov record NCT06616961, source copy `cardio:ctgov-nct06616961-2024-09-27`, retrieved 2026-11-18)
- Completion: 2026-10 (anticipated) (ClinicalTrials.gov record NCT06616961, source copy `cardio:ctgov-nct06616961-2024-09-27`, retrieved 2026-11-18)
- Countries: Bangladesh (ClinicalTrials.gov record NCT06616961, source copy `cardio:ctgov-nct06616961-2024-09-27`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06616961-2024-09-27`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
- Condition: Obesity
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): Semaglutide Pen
- Lead sponsor: Popular Medical College Hospital
- Lead sponsor class: OTHER
- Collaborator: Pi Research and Development Center, Bangladesh
- Collaborator class: UNKNOWN
- Collaborator: Incepta Pharmaceuticals Ltd
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)

## Provenance

Content hash: e59bcadce6027d73d2aed89f535916bd3f4042059695656107794562b519e83b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
